Clinical Trials Directory

Trials / Completed

CompletedNCT02404376

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
378 (actual)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Remote ischemic conditioning (RIC) and intravenous exenatide administered immediately before primary angioplasty have been found to limit infarct size in patients with STEMI (ST segment elevation myocardial infarction), but the reduction is limited. This study investigates whether a combination therapy including both therapies is more effective.

Detailed description

COMBAT-MI is an investigator-driven, randomized, double-blind and placebo-controlled clinical trial aimed at evaluating the effect of Remote Ischemic Conditioning and exenatide, alone and in combination, on Myocardial Infarct size in 428 STEMI patients (107 per group) (ST segment elevation myocardial infarction). Patients with TIMI (Thrombolysis in Myocardial Infarction) flow grade \> 1 will be excluded. The study has a 2 x 2 factorial design (Remote Ischemic Conditioning , Exenatide, both or neither). The primary end-point will be Myocardial Infarct size measured by Cardiac Magnetic Resonance Imaging (CMRI) performed 3 - 7 days after primary Percutaneous Coronary Intervention (pPCI) (expressed as % of left ventricular (LV) mass). Sample size has been calculated in 274 patients with TIMI 0-1 available for analysis of the primary end-point, and inclusion will end when this number is reached, which will require, according to the current rate of TIMI 0-1 in our STEMI population, to randomize 428 patients. Secondary end-points will include myocardial salvage index, based on angiographic and CMRI derived estimations of the area at risk, and frequency of Major Adverse Cardiovascular Events (MACE) and of major adverse events during admission.

Conditions

Interventions

TypeNameDescription
DRUGExenatideIntravenous administration of Exenatide
OTHERRemote Ischemic Conditioning (RIC)Remote ischemic conditioning with a cuff in the arm
DRUGPlaceboIntrevenous administration of Placebo

Timeline

Start date
2016-03-01
Primary completion
2019-08-01
Completion
2020-06-01
First posted
2015-03-31
Last updated
2020-11-03

Locations

6 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT02404376. Inclusion in this directory is not an endorsement.